VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
WVE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
WVEWave Life Sciences Ltd.
$2.84$546M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
WVE logo

Wave Life Sciences Ltd.

WVE
NASDAQ · Cell & Gene Therapy
$2.84
At close - Nov 17, 4:00 PM EST - USD
Market Cap$546M
P/E-2.8x
52W High$21.73
Volume2.78M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Volatile Milestone Revenue Masks Unprofitable Core Operations

Wave Life Sciences presents a high-risk profile, with its financials dominated by extreme revenue volatility from non-recurring licensing events rather than a stable commercial base, as evidenced by quarterly swings from -$7.7M to $83.7M.

GrowthMixed
ProfitabilityWeak
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

WVE price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

4/12 Beats

EPS beat 4 of last 12 quarters

02

Valuation risk

-108% Peers

P/E is 108% below peer median

03

Market leadership

RS 12 · Lag

Laggard (Underperforming 88% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Jan 27

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
WVE-82.19%
S&P 500 (^GSPC)+7.21%
1-Year Return
WVE-60.28%
S&P 500 (^GSPC)+10.03%
3-Year Return
WVE-48.46%
S&P 500 (^GSPC)+60.91%
5-Year Return
WVE-32.06%
S&P 500 (^GSPC)+61.91%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-2.8x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-2.8x
N/A
N/A
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$3.98+40.1%
Base (Fair)$5.14-5.0%
Bull$4.62+62.7%
$3.98 Bear$5.14 Base$4.62 Bull
Current Market Price: $2.84
Trades at a 44.7% discount to Base DCF ($5.14)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$43M-60.5% YoY
Net income FY25
-$204M-110.7% YoY
Free cash flow FY25
-$187M-23.4% YoY
Operating margin FY25
-504.1%-402.2 pts YoY
ROIC (FY25)-
Avg ROIC 5Y-
ROE (TTM)-44.5%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate4/12 (33%)
Revenue Beat Rate5/12 (42%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 27, 2026
-$0.30+8.8%
vs -$0.33
$13M+191.6%
vs $5M
Q3 2026
Jul 30, 2026
-$0.34-13.4%
vs -$0.30
$2M-69.5%
vs $7M
Q2 2026
Apr 28, 2026
-$0.13+61.8%
vs -$0.34
$38M+352.6%
vs $8M
Q1 2026
Feb 26, 2026
-$0.30-7.1%
vs -$0.28
$17M+7.4%
vs $16M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·Nov 4, 2026
Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript

Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript

MarketBeat·Nov 4, 2026
WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program

WAVE Life Sciences NASDAQ: WVE used its 2026 Research Day to outline plans for WVE-008, an RNA-editing candidate being developed for liver disease associated with the PNPLA3 I148M genetic variant, while also providing updates on its RNA interference, extrahepatic delivery and bifunctional oligonucleotide platforms.

Seeking Alpha·Oct 27, 2026
Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript

Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript

MarketBeat·Oct 27, 2026
WAVE Life Sciences Q3 Earnings Call Highlights

WAVE Life Sciences NASDAQ: WVE reported higher third-quarter revenue and a wider net loss as it increased investment in clinical programs spanning obesity, alpha-1 antitrypsin deficiency and liver disease.

Filtered for Wave Life Sciences Ltd.More Headlines
04

Compare before deciding

Benchmark WVE against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Wave Life Sciences Ltd. (WVE)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
WVE logoWVEWave Life Sciences Ltd.Current
$2.84$546.42M-2.75-60.55%-296.86%-44.48%—
SRPT logoSRPTSarepta Therapeutics, Inc.
$14.77$1.56B106.0315.58%0.75%1.04%—
IONS logoIONSIonis Pharmaceuticals, Inc.
$26.96$4.48B-8.2033.87%-56.9%-120.44%—
ARWR logoARWRArrowhead Pharmaceuticals, Inc.
$42.99$6.06B-8.41-45.65%-160.64%-172.62%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$9.78$1.1B-3.2216.92%-805.75%-64.73%—
BEAM logoBEAMBeam Therapeutics Inc.
$20.65$2.12B-20.19120.01%-73.04%-9.69%—

Compare WVE vs Peers

Wave Life Sciences Ltd. (WVE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SRPT

Most directly comparable listed peer for WVE.

Scale Benchmark

vs TMO

Larger-name benchmark to compare WVE against a more recognizable public peer.

Peer Set

Compare Top 5

vs SRPT, IONS, ARWR, NTLA

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

WVE SEC Filings & Documents

Wave Life Sciences Ltd. (WVE) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Jul 30, 2026·SEC

Material company update

Jun 26, 2026·SEC

Material company update

May 18, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Mar 4, 2025·SEC

FY 2024

Mar 6, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Jul 30, 2026·SEC

FY 2026

Apr 28, 2026·SEC

FY 2025

Nov 10, 2025·SEC

Get notified when WVE posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

WVE Frequently Asked Questions

Wave Life Sciences Ltd. (WVE) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Wave Life Sciences Ltd.'s revenue?

Wave Life Sciences Ltd. (WVE) reported $70.9M in revenue over the trailing twelve months. Revenue was $42.7M in fiscal year 2025.

How fast is Wave Life Sciences Ltd. growing?

Wave Life Sciences Ltd. (WVE) revenue fell by 35.1% over the trailing twelve months, compared with the twelve months before.

Is WVE profitable?

No. Wave Life Sciences Ltd. (WVE) reported a net loss of $210.5M over the trailing twelve months.

Dividend & Returns
What is WVE's return on equity?

Wave Life Sciences Ltd. (WVE) had a return on equity (ROE) of -44.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Wave Life Sciences Ltd.'s free cash flow?

Wave Life Sciences Ltd. (WVE) had negative free cash flow of $201.5M over the trailing twelve months.

What if you invested $1,000 in WVE back in 2013?

Total return calculator · dividends reinvested · 13+ years of data

See returns →